Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Ercan Taştan"'
Autor:
Abdurrahman Akyüz, Ferhat Işık, Burhan Aslan, Murat Çap, İlyas Kaya, Özgür Atlı, Ümit İnci, Ercan Taştan, Adem Aktan, Önder Bilge, Metin Okşul, Emre Aydın, Zülküf Karahan, Derya Deniz Altıntaş, Rojhat Altındağ, Mehmet Şahin Adıyaman, Bernas Altıntaş
Publikováno v:
Clinical and Experimental Hypertension, Vol 43, Iss 7, Pp 587-596 (2021)
Introduction We have aimed to investigate the relationship between use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin-receptor-blocker (ARB) drugs and acute hypoxemic respiratory failure (AHRF) and in-hospital mortality in hypertens
Externí odkaz:
https://doaj.org/article/c24853cd527c48f6ba7b456bd18ada5c
Autor:
Abdurrahman Akyüz, Murat Çap, Süleyman Varsak, Ferhat Işık, Askeri Turken, Ercan Taştan, Erkan Baysal
Publikováno v:
Journal of Clinical Ultrasound. 50:1242-1248
Cardiac involvement in limb-girdle muscular dystrophy (LGMD)2A and LGMD2B, the most common subgroups of LGMD, is controversial. Our study aims to determine whether myocardial dysfunction develops in LGMD2A and LGMD2B patients.The study included 16 LG
Autor:
Önder, Bilge, Halil, Kömek, Ferat, Kepenek, Ercan, Taştan, Cihan, Gündoğan, İsmail, Tatli, Cansu, Öztürk, Halil, Akin, Ferhat, Işik, Şeyhmus, Kavak, Burhan, Aslan, Abdurrahman, Akyüz, Neşe, Kanbal Çap, Emrah, Erdoğan
Publikováno v:
Nuclear Medicine Communications. 43:756-762
Objective We aimed to examine the effects of COVID-19 pneumonia on cardiac ischemia detected by myocardial perfusion imaging with single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in patients presenting with chest pa
Publikováno v:
Acta Medica. 53:30-36
Background and Aim: It is known that chronic heart failure reduces sleep quality by causing sleep problems. In recent years, it has been observed that sacubitril-valsartan, which is an angiotensin receptor neprilysin inhibitor, reduces mortality and
Autor:
Metin Okşul, Önder Bilge, Askeri Türken, Ferhat Işık, Abdurrahman Akyüz, Murat Çap, Serdar Söner, Halil Akın, Yusuf Z Şener, Ercan Taştan
Publikováno v:
Cureus.
Autor:
Emrah Erdoğan, Muhammed Süleymanoğlu, Murat Çap, Metin Okşul, İsmail Tatlı, Abdurrahman Akyüz, Cihan Gündoğan, Önder Bilge, Ibrahim Halil Tanboga, Mesut Oktay, Cansu Öztürk, Ercan Taştan, Ali Karagöz, Ferat Kepenek, Cengiz Burak, Ferhat Işık
Publikováno v:
The International Journal of Cardiovascular Imaging
We aimed to examine the effect of a history of COVID-19 on myocardial ischemia in single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in patients who presented with shortness of breath and/or chest pain after recover
Autor:
Özgür Atlı, Ümit İnci, Abdurrahman Akyüz, Adem Aktan, Metin Okşul, Emre Aydin, Ercan Taştan, İlyas Kaya, Derya Deniz Altıntaş, Bernas Altıntaş, Murat Çap, Rojhat Altındağ, Önder Bilge, Burhan Aslan, Zülküf Karahan, Ferhat Işık, Mehmet Şahin Adıyaman
Publikováno v:
Clinical and Experimental Hypertension
article-version (VoR) Version of Record
article-version (VoR) Version of Record
WOS:000648071100001 PMID: 33955313 Introduction We have aimed to investigate the relationship between use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin-receptor-blocker (ARB) drugs and acute hypoxemic respiratory failure (AHRF) and
Autor:
Önder Bilge, Murat Çap, Ferat Kepenek, Emrah Erdogan, İsmail Tatlı, Cansu Öztürk, Ercan Taştan, Cihan Gündoğan, Ferhat Işık, Metin Okşul, Mesut Oktay, Halil Akın, Cengiz Burak, Mehmet Zülküf Karahan, Halil Kömek, İbrahim Halil Tanboğa
Publikováno v:
Acta cardiologica.
Background Thrombolysis in Myocardial Infarction Frame Count (TFC) is an index that provides a quantitative evaluation of coronary microvascular dysfunction. In this study, we aimed to examine the effect of COVID-19 infection on TFC in patients admit
Publikováno v:
Turkish Journal of Clinics and Laboratory.
Autor:
Medet Akçay, Ercan Taştan, Önder Bilge, Muhammed Demir, Halil Akın, Ümit İnci, Halil Yıldız, Mehmet Özbek, Burhan Aslan, Ferhat Işık, Eşref Araç
Objective: In recent years, sodium-glucose cotransporter-2 (SGLT-2) inhibitors are known to improve symptoms and reduce mortality in patients with heart failure (HF). Empagliflozin is an antidiabetic drug that SGLT-2 inhibitor. Empagliflozin has bene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b433d363e2e733d2ce537197ce3c703
https://doi.org/10.21203/rs.3.rs-986178/v1
https://doi.org/10.21203/rs.3.rs-986178/v1